Last reviewed · How we verify

NCT06265792: OSA

Efficacy of Stellate Ganglion Block in Obstructive Sleep Apnea

Status unknown NA Last updated 6 March 2024
What this trial tests

NA trial testing routine rehabilitation treatment in Obstructive Sleep Apnea in 80 participants. Status unknown.

Timeline
1 March 2024
Primary endpoint
1 December 2024
15 December 2024

Quick facts

Lead sponsorZeng Changhao
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment80
Start date1 March 2024
Primary completion1 December 2024
Estimated completion15 December 2024
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Zeng Changhao — full company profile →

Who can join

18 and older, any sex, with Obstructive Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test the efficacy of stellate ganglion block in Obstructive Sleep Apnea. The main question it aims to answer are: • Can stellate ganglion block improve Obstructive Sleep Apnea? Patients were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of routine rehabilitation treatment

Trials testing the same drug.

Other recruiting trials for Obstructive Sleep Apnea

Currently open trials in the same condition.

Other Zeng Changhao trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06265792.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing